Other therapies aimed at restoring dystrophin function have been approved in recent years globally, although with limited success, as they are intended for use in ambulant DMD patients with specific mutations that only account for a small percentage of the DMD patient population (Yao et al., 2021). Here, DMD is linked to Duchenne muscular dystrophy.